| Code | CSB-RA006920MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to the reference antibody described in US9879072B2, specifically targeting Dickkopf-1 (DKK1), a secreted glycoprotein that functions as a potent antagonist of the canonical Wnt/β-catenin signaling pathway. DKK1 binds to LRP5/6 co-receptors, blocking Wnt ligand interaction and thereby inhibiting downstream signaling critical for bone formation, tissue homeostasis, and cellular differentiation. Aberrant DKK1 expression has been implicated in multiple pathological conditions, including osteoporosis, bone metastases, multiple myeloma, and various solid tumors where it contributes to osteolytic lesions and tumor progression. Additionally, elevated DKK1 levels are associated with fibrotic diseases and certain neurodegenerative conditions.
The reference antibody was developed as a therapeutic candidate for conditions involving dysregulated Wnt signaling and bone metabolism. This biosimilar provides researchers with a valuable tool for investigating DKK1-mediated mechanisms in cancer biology, bone disease, developmental biology, and regenerative medicine studies. It enables exploration of Wnt pathway modulation and assessment of DKK1 as a potential therapeutic target across diverse research models.
There are currently no reviews for this product.